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showed asymmetrical hyperintense signals in the
subcortical white matter of frontal, parietal and occipital
lobe and cerebellum. 
Conclusion
The current study presents the proportion of patients
suffering from each type of white matter disease. It also
demonstrates the effective use of the imaging and clinical
presentation in making the right diagnosis.
White matter diseases are a heterogeneous group of
disorders, where the main imaging finding is the abnormal
white matter. Although a clinical diagnosis is usually
present in these disorders, imaging reinforces the diagnosis
in many cases. Thereby, MRI imaging could play a pivotal
role in prompt treatment of patients with white matter
disease.
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Abstract
Heprovac B is a novel recombinant vaccine There are
many vaccines available in Pakistani market but Heprovac B
claims to be immunogenic even at 10 meg dose.Aim of the
study is to determine whether using 10 meg of Heprovac B
vaccine is safe and effective in producing sufficient
immunity in Pakistani population. One hundred and twenty
five subjects, who fulfilled the Inclusion criteria, were
enrolled for the study. Heprovac B was administered in a
three-dose regimen given at 0, 1 and 6 months and adverse
events were recorded. Immunogenicity was tested by
measuring hepatitis B surface antibody one month after each
dose received.One month after the 3rd dose 98.7% of the
subjects were found to be seroprotected with geometric
mean titer of 488.83 mIU/1 after the third dose. Heprovac B,
vaccine was well tolerated with minimal reported adverse
events. It is safe and 10mcg is immunogenic in producing
antibodies in Pakistani population against Hepatitis B virus.
Introduction
Hepatitis B virus infection is a major healthcare
issue that affects children and adults worldwide. Long term
infection can lead to chronic hepatitis, cirrhosis and primary
hepatocellular carcinoma.1 In Pakistan, Hepatitis B is one of
the major causes of chronic liver disease and hepatocellular
carcinoma. In Pakistan, the estimate is 4.5 million carriers,
with a carrier rate of 3-4%.2
Since, there is no definite treatment available yet,
great emphasis is being placed on its prevention through
immunization.3 Currently there are yeast derived vaccines
present in Pakistan. The immunogenicity of these vaccines
has been subjected to intense study since their birth. 
There are three forms of HBsAg that are expressed
in the hepatitis B vaccine, namely the major form consisting
of the S protein alone, the large form containing the preS1 -
preS2 - S components and a middle form containing pre S2
- S components. The presence of these conforms to the
Immunogenicity of the vaccine.4 The yeast cell recombinant
vaccines contain only the major form i.e. only protein S;
hence chances of failure of sero-conversion in these
vaccines does exist. 
The CHO cell derived vaccine, on the other hand,
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contains all the three forms of HBsAg and therefore is
highly immunogenic as compared to the plasma or yeast
recombinant vaccines. Several studies conducted in adults,
children and neonates showed that this vaccine is highly
immunogenic and safe.5-8
Heprovac B (Recombinant Transgenic CHO Cell
produce Hepatitis B Vaccine) is a non infectious subunit
viral vaccine consisting of major protein of surface antigen
(HBsAg) of HBV produced by a transgenic CHO cell line,
which has been transfected by a recombinant plasmid
containing a portion and been cloned.  The Heprovac B is
produced from cell cultures of Genetic Research Laboratory
of Institute of Virology of Chinese Academy of Preventive
Medicine.
The aim of this study was to determine whether the
vaccination for hepatitis B using 10 mcg of CHO derived
Heprovac B vaccine is able to produce sufficient immunity
in Pakistani population.
Subjects, Methods and Results
This study was performed at a settlement in rural
Sindh, near Hyderabad at Matiyari Sugar Mills, Matiyari .
The trial was conducted under the ICH, GCP rules and the
protocol was approved by the ethics review committee of
the Aga Khan University Hospital, Karachi. After informed
consent was obtained, blood samples were taken from each
individual aged between 20 and 60 years, irrespective of
gender. Initial HBsAg and HBsAb screening was done
using EIA Abbott kit at Aga Khan Laboratories. Titers were
expressed as milli international units per litre (mIU/L). A
total of 125 subjects, who were negative for both HBsAb
and HBsAg were enrolled in the study. Those subjects who
had previous history of vaccination for hepatitis B and those
found positive for HBsAb and HBsAg were excluded from
the study. All these selected subjects were given 10 mcg of
Heprovac B vaccine intramuscularly in the deltoid region at
the classical 0, 1, and 6 months schedule. Blood sample
were collected prior to the 2nd and 3rd and at 7th month to
see the antibody response. The main outcome was the
development of seroprotective levels of HBsAb in serum.
HBsAb > 10 mIU/L was considered as serprotection. Safety
was assessed in all the subjects by monitoring for 30
minutes after injection and local and systemic reactions for
three days after each injection were reported. They were
also asked to record any adverse events and illness that
required medical attention between day three after
vaccination and the next visit.  Statistical analysis was
preformed using SPSS version 11.
A total of 222 patients were screened out, of which
97 were excluded due to presence of positive results for
HBsAb or HBsAg or both. One hundred and twenty five
subjects with a mean age of 33.73 ± 10.33 years received a
10mcg dose for Heprovac-B vaccine at 0, 1 and 6 months.
Antibodies titers were checked after one month of each
dose. Twenty four subjects withdrew their consent after the
screening. One hundred and one subjects received the first
dose, 83 received the second dose and only 77 subjects
completed the study. Of all the 77 subjects vaccinated,
antibodies were successfully produced in 98.71% subjects
while 1.29% did not produce the required antibodies. 
In all these vaccinated subjects, > 10 mIU/L
antibodies were produced in 21.78% subjects after the first
dose, 68.67% after the second dose and 98.7% after the
third dose with 1.29% producing less than 10 mIU/L and
none produced antibodies after the third dose. Antibody
levels were divided into 5 categories i.e.  levels of less than
10 mIU, 10-100 mIU, 100-1000 mIU, over 1000 mIU and
no antibodies formed. 
Adverse events reported were mild local reactions
lasting for a day after vaccination and consisting mainly of
pain upon pressure and movement. No serious adverse
events were experienced. 
The Geometric mean of antibodies was 57.06 mIU/L
after the 1st dose, 119.41 mIU/L after the 2nd dose and
488.83 mIU/L after the 3rd dose as shown in Figure-1. 
The present study corroborates previous data
showing that a new recombinant hepatitis B virus vaccine
that contains the S-protein component of the HBV surface
together with the Pre-S1 and Pre-S2 is more immunogenic.
Several studies have been carried out in mice neonates and
children, as well as in adults.5,8 While the exact reason for
the improved immunogenicity of CHO derived Hepatitis B
vaccine are not completely understood, it is probably the
result of the spherical structure obtained by producing the
vaccine in an animal derived cell line (CHO) and from the
presence of the Pre-S1 and Pre-S2 proteins on the surface of
the vaccine particle.6 The importance of Pre-S domains in
the immunogenicity of HBV and the beneficial effect of an













Figure 1. GMT of Antibodies.
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Previously in a similar study, conducted in Karachi,
with the same vaccine, where the 0-1-6 months schedule
with 10 mcg was used in healthy individuals, an overall
seroprotection rate of 27.2% was obtained at day 30 after
the first dose, 72.8% after the second dose, 94.9% one
month after the third dose and 1.3% produced less than
10IU and 3.8% not producing antibodies after the third
dose.9 Our results, are consistent with these findings as
shown in Figure 2. Drug A being the drug used in this study.
The overall successful immunization was evident by the
production of adequate HBsAb titers  (98.7%) after the third
dose of the vaccine. This figure is close to and slightly better
than that of a previous study from PMRC, Karachi,
Pakistan9 using a dosage schedule similar to our study. 
In conclusion Heprovac B, a novel recombinant
DNA, CHO derived vaccine was well tolerated with
minimal reported adverse events, all of which subsided
rapidly. It is safe and 10mcg is immunogenic in producing
antibodies in Pakistani population against Hepatitis B virus.
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Figure 2. Efficacy comparison of  hepatitis B vaccines used in two different studies
(Drug A: used in this study. Drug B: used in study from PMRC, Karachi, Pakistan) 
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